2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Metabolism, Microbiome, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Health Outcomes Research, Study Population, Human, Adult, Animal Model
PAPER

4948 Identification of novel repsox congeners for therapeutic intervention in fpdmm likely by enhancing RUNX1:CBFß dimerization

Preetha Rani MR, PhD, Rhys Denver2, KIWON LEE, PhD3, Shekhar Kumar, PhD4, Paul Liu, MD, PhD5, Alan Cantor, MD, PhD6, Samarjit Patnaik7, Sara E. Kearney8, Mortimer Poncz, MD9
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Hankuk University of Foreign Studies, Yongin, Korea, Rep. of South
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 NIH-National Human Genome Research Institute, Rockville, Maryland, United States
6 Boston Children's Hospital, Boston, Massachusetts, United States
7 National Center for Advancing Translational Sciences, Bethesda, Maryland, United States
8 National Center for Advancing Translational Sciences, Bethesda, Maryland, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Background

Familial platelet disorder with associated myeloid malignancy (FPDMM) is caused by RUNX1 haploinsufficiency (RUNX1Lo) and is characterized clinically by defective megakaryopoiesis and platelet (Plt) biology with an increased risk of hematologic malignancies. Our previous studies showed that a small molecule RepSox, initially characterized as an ALK5 inhibitor, improved megakaryocyte (Mk) and Plt biology; however, this activity required high RepSox concentrations (1µM). Also, other ALK5 inhibitors were not effective. We proposed that RepSox may correct Mk and Plt biology by an alternative non-ALK5 pathway.

Aim

To identify and characterize novel RepSox congeners with enhanced potency in RUNX1 haploinsufficient cell models and to investigate their potential mechanism(s) of action.

Methods

Additional RepSox-related compounds were screened for their capacity to correct Mk yield from differentiated RUNX1LoCD34+-adult hematopoietic stem and progenitor cells (HSPCs) created using lentiviral short hairpin RNA (shRNA) targeting RUNX1 (shRX) or a non-targeting shRNA. 72 hrs after transduction, cells were treated with RepSox or its congeners until differentiated and Mk yield quantified. Lead candidates were then evaluated in iPSC patient-derived cell lines, and in HEL cells. Functional activity was assessed using a c-MPL promoter driven luciferase reporter assay. RUNX1 protein expression level in final Mks was quantified by flow cytometry. Molecular docking analysis using the predictive modelling program, AutoDock Vina v1.2.7, was performed against RUNX1 dimers and RUNX1:CBFβ heterodimers.

Results

Screening identified two RepSox congeners that corrected Mk yield as RepSox, but at lower concentrations and a third that had no efficacy in RUNX1Lo CD34+-cells-derived Mk yield: Compound NCGC00387472-01 (“472”) showed peaked potency at 0.01 µM whereas NCGC00384167-02 (“167”) was active at 500 nM. TPO427736 (“736”) was a related RepSox congener that bound as well as RepSox to ALK5 (better than 472 and 167), but that did not rescue Mk yield and served as a negative control. Both positive congeners also demonstrated efficacy in a patient-derived iPSC line and in HEL cells.

Functional assessment using luciferase reporter system showed that RepSox (1µM), 472 (0.01µM) and 167 (0.5µM) enhanced RUNX1 transcriptional activity by 2.5-fold, 2.6-fold and 1.8-fold, respectively, compared to control. Flow cytometric analysis demonstrated an increase in the RUNX1 protein expression during megakaryopoiesis following treatment with RepSox and with 472 and 167 at their active concentrations. Molecular docking showed weak binding affinity when the three active compounds and the negative control 736 were docked against RUNX1 dimers (ΔG ≈ -6.6 kcal/mol, estimated Kd ≈14.5 μM), but the three active compounds substantially improved interactions with RUNX1:CBFβ heterodimers at a specific pocket. RepSox: ΔG ≈ -7.9 kcal/mol (Kd ≈ 1.6 μM); 472: ΔG ≈ -7.9 kcal/mol (Kd ≈ 1.6 μM); and  167: ΔG ≈ -8.7 kcal/mol (Kd ≈ 0.4 µM). The negative control 736 had a ΔG ≈ -6.6 kcal/mol (Kd ≈ 14.7 μM). These data suggest that stabilization of RUNX1:CBFβ heteroduplexes by the small compounds may contribute to their corrective effect on Mk yield in the setting of RUNX1Lo.

Conclusions

We identified two novel RepSox congeners with enhanced improvement in RUNX1 activity in three distinct RUNX1Lomegakaryopoiesis models. Like RepSox but at lower concentrations, compounds 472 and 167 increased cMPL promoter RUNX1 activation and elevated RUNX1 protein expression. Docking studies suggest that interaction with the RUNX1:CBFβ heterodimer may underlie their mechanism of action rather than by inhibiting ALK5 activity. These finding support further preclinical evaluation of these compounds and rationally designing compounds with even greater and specific binding to the identified RUNX1:CBFβ pocket as a potential therapeutic strategy for FPDMM. 

Preetha Rani MR, PhD: No relevant conflicts of interest to declare.